Systemic Therapy in Metastatic Colorectal Cancer

MicroRNA‑3651 promotes colorectal cancer cell proliferation through directly repressing T‑box transcription factor 1

“…colorectal cancer is responsible for ~10% of mortalities associated with cancer and exhibits the second highest cancer mortality rate worldwide (1). conventional surgery, chemotherapy and radiotherapy are commonly used for the treatment of patients with colorectal cancer (2). Recently, targeted therapy against vascular endothelial growth factor and epidermal growth factor receptor in combination with chemotherapy has been demonstrated to prolong the overall survival of patients (3).…”

The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells

“…However whether p53 mutation is a possible predictor of response to chemotherapy in CRC is still uncertain. 5-Fluorouracil (5-FU) has been used as the ®rst-line medicine in the treatment of CRC for over three decades (Hansen 1990;Francini et al 1994) and hydroxycamptothecin (HCPT) has been used to treat advanced CRC in recent years (Conti et al 1996;Shimada et al 1993). To clarify the in¯uence of p53 status on the chemosensitivity of CRC, we have investigated the role of the p53 gene in the apoptosis of colorectal cancer cells in vitro induced by 5-FU and HCPT.…”

Anesthetic considerations for hepatic cryotherapy

“…In a majority of patients, unfortunately, circumstances such as involvement of nonresectable structures, general extent of disease, and multiple or bilobar lesions may preclude simple resection. Treatment modalities that have been considered alone and in various combinations for unresectable and recurrent disease include not only cryotherapy, but also regional [1,2] and systemic chemotherapy [3,4], chemoembolization [5], and external beam [6] and brachytherapy [7] radiation. The relative efficacy and appropriate patient selection criteria for these modalities have yet to be fully determined, but it does appear that hepatic cryotherapy is and will continue to be a superior treatment option for patients with nonresectable liver tumors [8][9][10].…”